Artiva Biotherapeutics Inc. (ARTV) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Artiva Biotherapeutics Inc. (NASDAQ: ARTV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $4.19 (-0.95% 1D, market cap $206.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTV ranks #553 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARTV carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PALI (Palisade Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M) and DTIL (Precision BioSciences Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per ARTV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817241), Artiva Biotherapeutics Inc. generated $0 in revenue (-100.0% YoY), -$83.9M in net income, and -$79.3M in free cash flow against $130.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 20.6 (OVERSOLD (<32))
20D Institutional Volume Accumulation (±12.5% realized swing band)
Capital intensity & 0% operating margin leave 16 pts on the table
While ARTV currently carries a cautious 39/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.11) and Max Pain ($4.40) forces dealer call-delta covering toward $15.26.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Artiva Biotherapeutics Inc. (ARTV) slipped -0.95% to $4.19, trading at 11% of its 52-week range ($2.96 – $14.53). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Australia report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Major M&A deals this week include: Blue Matter buys Cognite, RadNet acquires ONRAD, Oak Hill Capital buys Wyyerd.
Oct. 27, 2026 U.S. top movers: BRAI led gainers at 73.58%, while DVLT led losers at -49.02%, ranked by percentage change.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARTV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARTV. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Artiva Biotherapeutics Inc. (ARTV) ranks #553 by composite RQD confidence (39/100, grade D-) and #572 by equity capitalization ($206.8M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with ARTV at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ARTV
ACTIVE
Artiva Biotherapeutics Inc. | D- | 39/100 | — | — | -35.0% | -0.95% | $206.8M | Benchmark Subject |
| PALI Palisade Bio Inc. | D- | 43/100 | — | — | -35.0% | -2.52% | $207.4M | /pali-vs-artv → |
| DTIL Precision BioSciences Inc. | E | 24/100 | — | — | -35.0% | -5.11% | $205.4M | /dtil-vs-artv → |
| PLX Protalix BioTherapeutics Inc. | E | 28/100 | — | 48.8% | -13.0% | -0.77% | $210.3M | /plx-vs-artv → |
| CGEN Compugen Ltd. | B+ | 78/100 | 5.5x | 87.3% | 85.0% | -2.94% | $193.0M | /cgen-vs-artv → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artiva Biotherapeutics Inc. (ARTV) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $251.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$83.9M, operating cash flow of -$76.8M, and free cash flow of -$79.3M (-42.5% YoY). On the balance sheet, ARTV closed FY2025 with $130.9M in total assets against $0 in total debt (Altman Z-Score: 1.03, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$83.9M | -$76.8M | -$79.3M | $130.9M | — |
| FY2024 (FY) | 2024-12-31 | $251.0K | -$65.4M | -$55.0M | -$55.7M | $209.6M | — |
| FY2023 (FY) | 2023-12-31 | $32.9M | -$28.7M | -$47.4M | -$47.4M | — | — |
As of 2026-11-02, Artiva Biotherapeutics Inc. (NASDAQ: ARTV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $4.19 (-0.95% 1D, market cap $206.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTV ranks #553 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARTV carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PALI (Palisade Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M) and DTIL (Precision BioSciences Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per ARTV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817241), Artiva Biotherapeutics Inc. generated $0 in revenue (-100.0% YoY), -$83.9M in net income, and -$79.3M in free cash flow against $130.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ARTV last traded at $4.19 (-0.95% on volume of 1,966,179 shares), positioning the stock -48.34% below its 50-day simple moving average ($8.11) and -47.82% below its 200-day simple moving average ($8.03). Across its 52-week range of $2.96 to $14.53, ARTV sits at the 10.6% percentile with a 14-day RSI of 20.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.67 to $4.71).
Why ARTV Stock slipped -0.95% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ARTV carries an RQD Score of 39 out of 100, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
Investor implications: The combined rating points to a vulnerable balance sheet and weak cash flow. The sharpest upside driver would be a demonstrated clinical or commercial catalyst that restores investor confidence, but the recent news flow (Section: Recent Catalysts) points in the opposite direction. Valuation tradeoffs are significant: with no reported earnings and a negative ROIC, conventional earnings multiples cannot be computed from the source data.
Artiva Biotherapeutics Inc. (ARTV) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company's market capitalization is $0.2B. The source data does not describe the company's products, customers, or revenue model. Per the Financial Trend data, reported revenue fell from $32.9M in FY 2023 to $0.3M in FY 2024 and $0.0M in FY 2025, but the source data does not explain the sources of that revenue.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-89.8M | $-83.9M | N/A | $-79.3M | $26.7M | N/A |
| FY 2024 | $0.3M | $-67.3M | $-65.4M | N/A | $-55.7M | $40.2M | N/A |
| FY 2023 | $32.9M | $-30.7M | $-28.7M | N/A | $-47.4M | N/A | N/A |
Per the SEC financials, the company reported operating losses in each period shown, with net losses of $-83.9M in FY 2025 and $-65.4M in FY 2024. Gross, operating, and net margins are each listed as 0% in the market data, and ROIC is -35%. Per the forensic balance sheet inputs in the RQD rating, the Altman Z-Score is 1.03, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported cash declined from $40.2M in FY 2024 to $26.7M in FY 2025, and the source data does not provide FY 2023 cash or any period's debt figure.
Per the recent news and catalysts feed, the dominant items are negative:
Per the Butterfly Supply-Chain Graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals.
Per the Butterfly Supply-Chain Graph, no upstream or downstream links, supply-chain dependencies, or proprietary signals are mapped for ARTV. Sector and industry classification (Health Care; Biological Products) are the only structural data available. For a prospective investor, the most relevant second-order watch item is the news flow itself: the workforce reduction and discontinuation of the lead asset imply that the company's operating footprint and pipeline are contracting, which the source data does not quantify. Investors should monitor whether reported cash of $26.7M (FY 2025) is sufficient relative to the FY 2025 FCF of $-79.3M, since the source data does not establish a funding runway.
Real-time company headlines, analyst actions, and sector developments for Artiva Biotherapeutics Inc. (ARTV) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Australia report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Artiva Biotherapeutics Inc. (ARTV) market action, institutional positioning, and fundamental catalysts.
Welcome to the ARTV (Artiva Biotherapeutics Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ARTV, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Artiva Biotherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ARTV, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $4.19 (52-wk range $2.96 - $14.53), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).